Pentosan Polysulfate: A Different Approach to Osteoarthritis and Joint Degeneration *Educational Purposes Only*
For decades, the conventional approach to osteoarthritis has focused primarily on controlling symptoms. Patients are told to lose weight, modify activity, take anti-inflammatory medications, consider corticosteroid injections, and eventually, when the joint becomes sufficiently damaged, discuss joint replacement.
At RegeneZone®, I look at osteoarthritis differently.
Osteoarthritis is not simply a problem of pain. It is a complex biological process involving cartilage breakdown, inflammation of the synovium, changes within the subchondral bone, altered joint mechanics, and progressive disruption of the extracellular matrix that gives cartilage its structure and resilience.
This is why I have become increasingly interested in pentosan polysulfate sodium (PPS) as part of a comprehensive strategy for patients with osteoarthritis.
What Is Pentosan Polysulfate?
Pentosan polysulfate is a semi-synthetic sulfated polysaccharide derived from plant-based hemicellulose. It has been used medically for decades and has several biological properties that make it particularly interesting in the treatment of degenerative joint disease.
In the United States, oral pentosan polysulfate is FDA-approved for interstitial cystitis. Its use as a systemic treatment for osteoarthritis, however, is not currently FDA-approved. Injectable PPS is being actively studied as a potential treatment for knee osteoarthritis, including in large clinical development programs. (ClinicalTrials.gov)
What makes pentosan intriguing is that it may do considerably more than temporarily suppress pain.
Osteoarthritis Is a Biological Disease
Healthy cartilage is an extraordinarily sophisticated tissue. Chondrocytes live within an extracellular matrix composed largely of collagen and proteoglycans. That matrix allows cartilage to absorb tremendous mechanical forces while providing an exceptionally low-friction surface.
With osteoarthritis, this environment gradually changes.
Inflammatory signaling increases. Matrix-degrading enzymes become more active. Proteoglycans are lost. Cartilage becomes less resilient. Synovial inflammation develops, and the underlying subchondral bone begins remodeling.
The result is a cycle:
Inflammation → matrix degradation → altered biomechanics → additional tissue damage → more inflammation.
Simply reducing pain does not necessarily interrupt that cycle.
The goal of modern regenerative medicine should therefore be broader: improve the biological environment of the joint while simultaneously addressing its structural and mechanical problems.
That is where pentosan becomes particularly interesting.
How Pentosan May Work
Pentosan has several proposed mechanisms relevant to osteoarthritis.
Research suggests PPS may influence inflammatory mediators and enzymes involved in cartilage degradation, including pathways involving IL-1, TNF-alpha and matrix metalloproteinases. Experimental work has also suggested effects on proteoglycan metabolism and the extracellular cartilage matrix. (PubMed)
In other words, pentosan may influence the environment in which cartilage is being broken down.
There is also evidence suggesting effects on subchondral circulation and vascular biology. This is important because cartilage does not exist in isolation. The cartilage, synovium and underlying bone function as an interconnected biological unit.
More recently, researchers have begun looking directly at biomarkers inside the joint.
A 2026 randomized, double-blind phase 2 study examined synovial fluid biomarkers in patients with moderate-to-severe knee osteoarthritis. Injectable PPS was associated with changes in biomarkers related to cartilage metabolism, including a statistically significant reduction in ARGS, a marker associated with aggrecan degradation. (PubMed)
That does not prove that pentosan regenerates cartilage. But it supports the idea that PPS may be influencing the biology of cartilage degradation rather than acting merely as an analgesic.
What Have Human Studies Shown?
One of the earlier controlled studies included 114 patients with knee osteoarthritis. Participants received either intramuscular PPS at 3 mg/kg once weekly for four weeks or control treatment.
Patients receiving PPS experienced improvements in several measures, including joint stiffness and pain at rest, with some benefits persisting well beyond the treatment period. Functional improvements were also observed. (PubMed)
Another open clinical trial evaluated 20 patients with knee osteoarthritis using 2 mg/kg subcutaneously once weekly for six weeks. Investigators reported improvements in pain, function and joint effusion, with clinical improvements persisting for months in some patients. (PubMed)
A 2023 pilot study also found significant reductions in knee pain among patients with osteoarthritis and dyslipidemia treated with oral PPS, although this was a small, non-randomized study and should be interpreted accordingly. (PubMed)
Most importantly, pentosan continues to move through clinical investigation. Current and recent trials are evaluating subcutaneous PPS specifically for knee osteoarthritis pain, including six-week treatment protocols and longer follow-up designed to determine how durable the response may be. (ClinicalTrials.gov)
Why I Find Pentosan Particularly Interesting
I do not view pentosan as a replacement for regenerative joint procedures.
I see it as potentially addressing a different part of the problem.
When I evaluate an osteoarthritic joint, I think about several components simultaneously: systemic inflammation, synovial inflammation, cartilage metabolism, extracellular matrix integrity, subchondral bone, mechanical stability, muscular function and the biological signaling required for tissue repair.
A regenerative injection can address the local joint environment, but osteoarthritis is rarely just a single-site problem.
Pentosan offers the possibility of providing a systemic biological intervention alongside our local regenerative strategies.
This creates an important distinction between treating pain and treating the environment producing the pain.
How We Incorporate Pentosan Into Our Approach
At RegeneZone®, our philosophy is that osteoarthritis treatment should be layered rather than dependent upon a single procedure.
For appropriately selected patients, I may incorporate a course of pentosan alongside nutritional optimization, reduction of systemic inflammation, resistance training and rehabilitation, photobiomodulation, peptide strategies when appropriate, and image-guided regenerative procedures.
A protocol I use clinically is:
Pentosan polysulfate: 3 mg/kg once weekly for six weeks.
This is an individualized, off-label approach rather than an FDA-approved osteoarthritis regimen, and patient selection and medical monitoring are important. Published clinical studies have used different doses, routes and schedules, so there is not yet a universally established PPS protocol for osteoarthritis. (PubMed)
Because PPS has anticoagulant and antithrombotic activity, bleeding risk, concomitant anticoagulant or antiplatelet therapy, upcoming surgery, hematologic abnormalities and other contraindications need to be considered before treatment. In the six-week open knee OA study, coagulation parameters were measurably affected, although they remained within the investigators' safety parameters. (PubMed)
Pentosan and the Future of Osteoarthritis Treatment
I believe the future of osteoarthritis treatment will increasingly move away from the simplistic question:
“What can we inject into the knee to make it hurt less?”
The better question is:
“How do we change the biological environment that allowed this joint to degenerate in the first place?”
That requires thinking about inflammation, metabolic health, cartilage biology, extracellular matrix integrity, mechanical loading, subchondral bone, muscle strength and regenerative signaling as interconnected systems.
Pentosan polysulfate is interesting because it potentially fits within this broader biological model.
We should also be careful not to get ahead of the science. PPS is not currently an FDA-approved disease-modifying treatment for osteoarthritis, and the existing evidence does not justify claiming that it regrows cartilage or reverses advanced arthritis. Larger controlled trials are necessary to determine exactly where it belongs in osteoarthritis treatment.
But the emerging research is compelling enough that I believe pentosan deserves serious attention.
For selected patients, the objective is not simply to cover up pain. It is to create the healthiest biological environment possible for the joint, protect the tissue that remains, improve function and then use regenerative medicine strategically when additional structural or biological support is needed.
That is the philosophy behind our approach at RegeneZone®: treat the biology, address the structure, restore function, and give the body the best possible environment in which to heal.
References
Ghosh P. The pathobiology of osteoarthritis and the rationale for the use of pentosan polysulfate for its treatment. Semin Arthritis Rheum. 1999. (PubMed)
Kumagai K, et al. Sodium pentosan polysulfate resulted in cartilage improvement in knee osteoarthritis—an open clinical trial. BMC Clin Pharmacol. 2010. (PubMed)
Ghosh P, et al. Effects of pentosan polysulfate in osteoarthritis of the knee: a randomized, double-blind, placebo-controlled pilot study. (PubMed)
Liu X, et al. The effect of pentosan polysulfate sodium for improving dyslipidaemia and knee pain in people with knee osteoarthritis: a pilot study. Osteoarthritis and Cartilage Open. 2023. (PubMed)
Effects of pentosan polysulfate sodium on synovial fluid biomarkers in moderate to severe knee osteoarthritis: an exploratory, phase 2, randomized, double-blind, placebo-controlled trial. 2026. (PubMed)
